---
audienceLevel: patient
cancerTypes:
- lung
- colorectal
- liver
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Ramucirumab - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/ramucirumab
version: v1
---

# Ramucirumab - NCI

# Ramucirumab

Placeholder slot

(RA-myoo-SIR-yoo-mab)

Ramucirumab works by blocking a protein called VEGFR-2, which some cancer cells produce in large amounts. Blocking VEGFR-2 may prevent the growth of new blood vessels that tumors need to grow. Ramucirumab is a type of targeted therapy drug called an angiogenesis inhibitor.

US Brand Name(s)

Cyramza

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6080942-dee6-423e-b688-1272c2ae90d4&audience=consumer)

## Use in Cancer

Ramucirumab
is approved
to be used alone or with other drugs to treat:

- **[Colorectal cancer](/Common/PopUps/popDefinition.aspx?id=444983&version=Patient&language=English)** that has [metastasized](/Common/PopUps/popDefinition.aspx?id=46283&version=Patient&language=English). It is used with [FOLFIRI](/Common/PopUps/popDefinition.aspx?id=635808&version=Patient&language=English) in patients whose disease has gotten worse during or after treatment with [bevacizumab](/Common/PopUps/popDefinition.aspx?id=46115&version=Patient&language=English), [oxaliplatin](/Common/PopUps/popDefinition.aspx?id=45465&version=Patient&language=English), and a [fluoropyrimidine](/Common/PopUps/popDefinition.aspx?id=386207&version=Patient&language=English).
- **[Hepatocellular carcinoma](/Common/PopUps/popDefinition.aspx?id=46363&version=Patient&language=English)** (a type of [liver cancer](/Common/PopUps/popDefinition.aspx?id=44242&version=Patient&language=English)). It is used alone in patients who have a high level of [alpha-fetoprotein](/Common/PopUps/popDefinition.aspx?id=46208&version=Patient&language=English) in the blood and have been treated with [sorafenib tosylate](/Common/PopUps/popDefinition.aspx?id=509041&version=Patient&language=English).
- **[Non-small cell lung cancer](/Common/PopUps/popDefinition.aspx?id=45323&version=Patient&language=English)** that has metastasized. It is used:
- With [erlotinib hydrochloride](/Common/PopUps/popDefinition.aspx?id=508929&version=Patient&language=English) as [first-line therapy](/Common/PopUps/popDefinition.aspx?id=346494&version=Patient&language=English) in patients whose disease has certain [mutations](/Common/PopUps/popDefinition.aspx?id=46063&version=Patient&language=English) in the *[EGFR](/Common/PopUps/popDefinition.aspx?id=796876&version=Patient&language=English)* gene.
- With [docetaxel](/Common/PopUps/popDefinition.aspx?id=45382&version=Patient&language=English) in patients whose disease has gotten worse during or after treatment with [platinum](/Common/PopUps/popDefinition.aspx?id=45841&version=Patient&language=English) chemotherapy. For patients whose disease has a mutation in the *EGFR* gene or *[ALK](/Common/PopUps/popDefinition.aspx?id=721252&version=Patient&language=English)* gene, ramucirumab is used if their disease has gotten worse after treatment with [FDA](/Common/PopUps/popDefinition.aspx?id=454786&version=Patient&language=English)-approved therapy for these mutations.
- **[Stomach](/Common/PopUps/popDefinition.aspx?id=445087&version=Patient&language=English) [adenocarcinoma](/Common/PopUps/popDefinition.aspx?id=46216&version=Patient&language=English)** or **[gastroesophageal junction](/Common/PopUps/popDefinition.aspx?id=302458&version=Patient&language=English) adenocarcinoma** (a rare type of [esophageal cancer](/Common/PopUps/popDefinition.aspx?id=444989&version=Patient&language=English)) that is [advanced](/Common/PopUps/popDefinition.aspx?id=478743&version=Patient&language=English) or has metastasized (spread to other parts of the body). It is used in patients whose disease has gotten worse after treatment with a fluoropyrimidine or platinum chemotherapy. It is used alone or with [paclitaxel](/Common/PopUps/popDefinition.aspx?id=45258&version=Patient&language=English).

Ramucirumab
is also being studied in the treatment of other types of
cancer.

## More About Ramucirumab

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/570535) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Ramucirumab](https://medlineplus.gov/druginfo/meds/a614026.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

[Immune Checkpoint Inhibitors](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors)

[Angiogenesis Inhibitors](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/angiogenesis-inhibitors-fact-sheet)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Ramucirumab](https://www.cancer.gov/research/participate/clinical-trials/intervention/C70792) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
